1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1H)-carbonitrile as USP30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis

Patent Citations (55)

Non-Patent Literature (64)

• The International Search Report and Written Opinion, mailed on Aug. 20, 2021, in the corresponding PCT Appl. No. PCT/EP2021/065112.Applicant
• Falgueyret et al., “Novel, Nonpeptidic Cyanamides as Potent and Reversible Inhibitors of Human Cathepsins K and L,” J. Med. Chem. 2001, 44, 94-104.Applicant
• Laine et al., “Discovery of Novel Cyanamide-Based Inhibitors of Cathepsin C,” ACS Med. Chem. Lett. 2011, 2, 142-147.Applicant
• Clague et al., “Deubiquitylases from genes to organism”, Physiol. Rev. 93:1289-1315, 2013.Applicant
• Rydzewski et al, “Peptidic 1-Cyanopyrrolidines: Synthesis and SAR of a Series of Potent, Selective Cathepsin Inhibitors”, Bioorganic & Medicinal Chemistry 10 (2002) 3277-3284.Applicant
• Deaton et al, “Novel and potent cyclic cyanamide-based cathepsin K inhibitors”, Bioorganic & Medicinal Chemistry Letters 15 (2005) 1815-1819.Applicant
• Oballa et al, “A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds”, Bioorganic & Medicinal Chemistry Letters 17 (2007) 998-1002.Applicant
• Zapf et al, “Covalent Inhibitors of Interleukin-2 Inducible T Cell Kinase (ltk) with Nanomolar Potency in a Whole-Blood Assay”, J. Med. Chem. 2012, 55, 10047-10063.Applicant
• Nakamura et al, “Regulation of Mitochondrial Morphology by USP30, a Deubiquitinating Enzyme Present in the Mitochondrial Outer Membrane”, Molecular Biology of the Cell, vol. 19, 1903-1911, May 2008.Applicant
• Bingol et al, “The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy”, Nature vol. 510, 370-375, 2014.Applicant
• Liang et al, “USP30 deubiquitylates mitochondrial Parkin substrates and restricts apoptotic cell death”, EMBO Reports, 1-10, 2015; DOI 10.15252/embr.201439820.Applicant
• Bedford et al., “Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets,” Nat Rev Drug Discov. Jan. 2011;10(1):29-46.Applicant
• Wynn, Thomas A., “Fibrotic disease and the TH1/TH2 paradigm”, Nat Rev Immunol. Aug. 2004 ; 4(8): 583-594.Applicant
• Ward et al., “Quantitative Chemical Proteomic Profiling of Ubiquitin Specific Proteases in Intact Cancer Cells,” ACS Chem. Biol. 2016, 11, 3268-3272.Applicant
• Cai Yu et al, “Smurf2, an E3 ubiquitin ligase, interacts with PDE4B and attenuates liver fibrosis through miR-132 mediated CTGF inhibition”, Biochimica et Biophysica Acta. Molecular Cell Research, vol. 1865, No. 2, Oct. 31, 2017, pp. 297-308.Applicant
• Krabill et al, “Biochemical and cellular characterization of a cyanopyrrolidine covalent Ubiquitin C-terminal hydrolase L1 Inhibitor”, ChemBioChem, Aug. 2019, 21(5).Applicant
• Kurita Y., et al., “Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy”, Respiratory Research (2017) 18:114.Applicant
• Williams J.A. et.al. “Targeting Pink1-Parkin-Mediated Mitophagy for Treating Liver Injury”, Pharmacol Res. Dec. 2015, 102: 264-269.Applicant
• Williams J.A. et.al. “A Mechanistic Review of Mitophagy and Its Role in Protection against Alcoholic Liver Disease”, Biomolecules 2015, 5, 2619-2642.Applicant
• Williams J.A. et.al. “Parkin regulates mitophagy and mitochondrial function to protect against alcohol-induced liver injury and steatosis in mice”, Am J Physiol Gastrointest Liver Physiol 309: G324-G340, 2015.Applicant
• Larson-Casey et al., “Macrophage Akt1 Kinase-Mediated Mitophagy Modulates Apoptosis Resistance and Pulmonary Fibrosis,” 2016, Immunity 44, 582-596.Applicant
• Tang et al., “Mitophagy: Basic Mechanism and Potential Role in Kidney Diseases,” Kidney Diseases 2015, 1, 71-79.Applicant
• Kluge, “Novel highly selective inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagy”, Bioorganic & Medicinal Chemistry Letters, 2018, 28 2655-2659.Applicant
• Thompson, www.Mednous.com, “Mitochondrial-quality-control-as-potential-therapy,” Mar. 2018.Applicant
• Silverman, R. “The Organic Chemistry of Drug Design and Drug Action”, 2004, NY Elsevier, pp. 29-32.Applicant
• Meanwell, N.,“Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design,” J.Med.Chem., 54, 2011, pp. 2529-2591.Applicant
• Phu et al, “Dynamic Regulation of Mitochondrial Import by the Ubiquitin System,” 2020, Molecular Cell 77, 1107-1123.Applicant
• Rusilowicz-Jones, “A novel USP30 inhibitor recapitulates genetic loss of USP30 and sets the trigger for PINK1-PARKIN amplification of mitochondrial ubiquitylation,” 2020, bioRxiv Apr. 16, 2020.Applicant
• Gersch et al, “Mechanism and regulation of the Lys6-selective deubiquitinase USP30,” 2017, Nat Struct Mol Biol 24 (11): 920-930.Applicant
• Cunningham et al, “USP30 and parkin homeostatically regulate atypical ubiquitin chains on mitochondria,” 2015, Nat Cell Biol 17(2): 160-169.Applicant
• Jacoupy et al, “The PINK1 kinase-driven ubiquitin ligase Parkin promotes mitochondrial protein import through the presequence pathway in living cells,” 2019, Sci Rep 9(1): 11829.Applicant
• Riccio et al, “Deubiquitinating enzyme USP30 maintains basal peroxisome abundance by regulating pexophagy,” 2019, J Cell Biol 218(3): 798-807.Applicant
• Luciani et al,“Impaired mitophagy links mitochondrial disease to epithelial stress in methylmalonyl-CoA mutase deficiency,” 2020, Nat. Commun. 11, 970.Applicant
• Mehta et al,International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology, 2015, Lancet 385(9987): 2616-2643.Applicant
• Chawla et al, “Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup,” Apr. 2017, Nat Rev Nephrol 13(4): 241-257.Applicant
• McWilliams et al, “Basal Mitophagy Occurs Independently of PINK1 in Mouse Tissues of High Metabolic Demand,” Feb. 6, 2018, Cell Metab 27(2): 439-449 e435.Applicant
• Emma et al, “Mitochondrial dysfunction in inherited renal disease and acute kidney injury,” May 2016, Nat Rev Nephrol 12(5): 267-280.Applicant
• Eirin et al, “The Emerging Role of Mitochondrial Targeting in Kidney Disease,” Aug. 12, 2017, Handb Exp Pharmacol 240: 229-250.Applicant
• Kawakami et al, “Deficient Autophagy Results in Mitochondrial Dysfunction and FSGS,” 2015, J Am Soc Nephrol 26 (5): 1040-1052.Applicant
• Connor et al, “Mutations in mitochondrial DNA causing tubulointerstitial kidney disease,” Mar. 7, 2017, PLoS Genet 13(3): e1006620.Applicant
• Tang et al, “PINK1-PRKN/PARK2 pathway of mitophagy is activated to protect against renal ischemia-reperfusion injury,” 2018, Autophagy 14(5): 880-897.Applicant
• Wang et al, “PINK1/Parkin-mediated mitophagy is activated in cisplatin nephrotoxicity to protect against kidney injury,” 2018, Cell Death Dis 9(11): 1113.Applicant
• Kobayashi et al, “Involvement of PARK2-Mediated Mitophagy in Idiopathic Pulmonary Fibrosis Pathogenesis,” Jun. 2016, J Immunol, 197:504-516.Applicant
• Araya et al, “PRKN-regulated mitophagy and cellular senescence during COPD pathogenesis,” 2019, Autophagy 15 (3): 510-526.Applicant
• Nishida et al, “Spontaneous onset of nonalcoholic steatohepatitis and hepatocellular carcinoma in a mouse model of metabolic syndrome,” 2013, Lab Invest; Feb. 93(2):230-41.Applicant
• Karuppagouner et al, “The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease,” Sci Rep. May 2, 2014;4:4874.Applicant
• Kruse et al, “Mice with Mitochondrial Complex I Deficiency Develop a Fatal Encephalomyopathy,” Apr. 2008, Cell Metab. Apr;7(4):312-20.Applicant
• Kobilo et al, “AMPK agonist AICAR improves cognition and motor coordination in young and aged mice,” 2014, Learn Mem. Jan. 17;21(2):119-26.Applicant
• Creed et al,“Basal and Evoked Neurotransmitter Levels in Parkin, DJ-1, PINK1 and LRRK2 Knockout Rat Striatum,” Neuroscience. Jun. 15, 2019;409:169-179.Applicant
• Van Skike et al, “mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging,” Jun. 18, 2019, Aging Cell. 19; e13057.Applicant
• Chevalier et al, “Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy,” Apr. 1, 2009, Kidney Int 75(11): 1145-1152.Applicant
• Lu et al.,“C57BL/6 and 129/Sv mice: genetic difference to renal ischemia-reperfusion,” 2012. J Nephrol. 25 (5): 738-45.Applicant
• Harrigan J.A. et al, “Deubiquitylating enzymes and drug discovery: emerging opportunities.”, Nat Rev Drug Discov. Jan. 2018;17(1):57-78.Applicant
• Morgan et al, “A Solid-Phase Route to N-Cyanoamides,” Organic Letters, 2002, 4(4), 597-598.Applicant
• Kemp et al, “Recent Advances in the Discovery of Deubiquitinating Enzyme Inhibitors”, Progress in Medicinal Chemistry, 2016, 55, 149-192.Applicant
• Jacq et al, “Deubiquitylating Enzymes and DNA Damage Response Pathways,” Cell Biochem Biophys, May 28, 2013, 67:25-43.Applicant
• Rusilowicz-Jones, “USP30 sets a trigger threshold for PINK1-PARKIN amplification of mitochondrial ubiquitylation.”, Life Science Alliance Jul. 2020, 3 (8) e202000768; DOI: 10.26508/lsa.202000768.Applicant
• Liu et al, “Deubiquitinase Activity Profiling Identifies UCHL1 as a Candidate Oncoprotein That Promotes TGFb-Induced Breast Cancer Metastasis”, Clin Cancer Res 2020;26:1460-1473.Applicant
• Bashore et al, “Cyanopyrrolidine Inhibitors of Ubiquitin Specific Protease 7 Mediate Desulfhydration of the Active-Site Cysteine”, ACS Chem. Biol. 2020, 15, 6, 1392-1400.Applicant
• Bashore et al, “Cyanopyrrolidine Inhibitors of Ubiquitin Specific Protease 7 Mediate Desulfhydration of the Active-Site Cysteine”, ACS Chem. Biol. 2020, 15, 6, 1392-1400. (Supporting Information).Applicant
• Yue et al, “A small natural molecule promotes mitochondrial fusion through inhibition of the deubiquitinase USP30”, Cell Research, 2014, 24, 482-496.Applicant
• Tsefou et al, “Investigation of USP30 inhibition to enhance Parkin-mediated mitophagy: tools and approaches,” bioRxiv, Feb. 2, 2021, https://doi.org/10.1101/2021.02.02.429344.Applicant
• Kellum et al, “Targeting acute kidney injury in COVID-19,” Nephrol Dial Transplant (2020) 35: 1652-1662.Applicant
• Mora et al., “Mitochondria in the spotlight of aging and idiopathic pulmonary fibrosis,” J Clin Invest, Feb. 1, 2017, 127 (2), pp. 405-414.Applicant